Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1997-03-07
1999-02-16
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
A61K 3119
Patent
active
058721517
ABSTRACT:
The present invention relates to the use of 4-(2-formyl-3-hydroxyphenoxymethyl) benzoic acid or physiologically acceptable salts thereof as an immunopotentiatory agent, compositions containing such a compound and their manufacture, combinations of such a compound with anti-tumour or anti-infective drugs and the use of such combinations in the prophylaxis or treatment of such diseases arising from tumours or infections.
REFERENCES:
patent: 4535183 (1985-08-01), Kneen
Database Phind, Dialog Accession No. 321226, "Wellcome's Antisickling Agent Trial",Sep., 1992.
Rolan et al, Br. J. Clin. Phamacol, 35, No. 4, Apr. 1993.
Database Pharmaproject; PJB Publications Ltd., Richmond, Surrey, U.K.; Dialog Acc. Nr. 11933; May 4, 1993, tucaresol *abstract* & Pharmaprojects Updated May 4, 1993.
Database Phind: Pharmaceutical & Healthcare Industry News Database; Dialog accession No. 321226; Wellcome's antisickling agent trial; *abstract* & SCRIPT; vol. 1751, Sep. 2, 1992, p. 26. no date.
Int. J. Radia. Oncol. Biol. Phys.; vol. 16, No. 5, 1989; pp. 1179-1182; G.E. Adams et al.; Induction of severe tumor hypoxia by modifiers of the oxygen affinity of hemoglobin; the whole document.
European Search Report; International Application No. PCT/GB93/02039; Date of mailing Mar. 29, 1993; International filing date Sep. 30, 1993.
European Search Report; EP 93 30 7373; date of completion of search, Jan. 17, 1994.
I.J. Radiation Oncology Bio. Phys. vol. 16, pp. 1179-1182; may 1989; No. 5.; G.E. Adams, D. Sc., et al.; Induction of Severe Tumor Hypoxia by Modifiers of the Oxygen Affinity of Hemoglobin.
European Search Report PCT/GB91/01394; date of completion of search Nov. 20, 1991; date of mailing Dec. 4, 1991.
J. of Immunology vol. 143; pp. 1482-1489; No. 5; Sep.; John Rhodes Evidence for an Intercellular Covalent Reaction Essential Antigen-Specific T Cell Activation.
Radiotherapy & Oncology. vol. 16, 1989; pp. 235-243; Elseiver; Shirly Cole.
J. of Immunology, vol. 139; pp. 2845-2849; Nov. 1, 1987; R. Hess et al.; Immunosuppression by Succinulacetone.
Helv. Chim Acta 19: pp. 1095-1107 (1936); A. Girard and G. Sandulesco.
J. Lab Cln, Med. vol. 99; Nov. 4; pp. 526-532; Immunosupressive activity of succinylacetone.
J. Exp. Med. vol. 162; Sep. 1985; pp. 1060-1074; S. Manabe et al.; Hereditary Tyrosinemia.
Translation of European patent application Publication No. 0 217 041 A; Apr, 8, 1987; 6 pages.
American Cancer Society, vol. 45, No. 8 Aliza Adler et al.; pp. 2061-2073; Immunocompetence, Immunosuppression, and Human Breast Cancer.
Database Pharmaproject; PJB Publications Ltd.; Richmond, Surrey, U.K.; Dialog Acc. Nr. 11933; May 4, 1993, tucaresol *abstract* & Pharmaprojects Updated May 4, 1993.
Int. J. Radia. Oncol. Biol. Phys.; vol. 16, No. 5, 1989, pp. 1179-1182; G.E. Adams et al.; Induction of severe tumor hypoxia by modifiers of the oxygen affinity of hemoglobin; the whole document.
Glaxo Wellcome Inc.
Goldberg Jerome D.
LandOfFree
Immunopotentiatory agents and physiologically acceptable salts t does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunopotentiatory agents and physiologically acceptable salts t, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunopotentiatory agents and physiologically acceptable salts t will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2062833